Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Mar;17(3):285-91.
doi: 10.1093/ntr/ntu141. Epub 2014 Sep 4.

Correlates and prevalence of menthol cigarette use among adults with serious mental illness

Kelly C Young-Wolff  1 , Norval J Hickman 3rd  2 , Romina Kim  3 , Kathleen Gali  4 , Judith J Prochaska  5
Affiliations
Clinical Trial

Correlates and prevalence of menthol cigarette use among adults with serious mental illness

Kelly C Young-Wolff et al. Nicotine Tob Res. 2015 Mar.

Abstract

Introduction: With a focus on protecting vulnerable groups from initiating and continuing tobacco use, the FDA has been considering the regulation of menthol in cigarettes. Using a large sample of adult smokers with serious mental illness (SMI) in the San Francisco Bay Area, we examined demographic and clinical correlates of menthol use, and we compared the prevalence of menthol use among our study participants to that of adult smokers in the general population in California.

Methods: Adult smokers with SMI (N = 1,042) were recruited from 7 acute inpatient psychiatric units in the San Francisco Bay Area. Demographic, tobacco, and clinical correlates of menthol use were examined with bivariate and multivariate logistic regression analyses, and prevalence of menthol use was compared within racial/ethnic groups to California population estimates from the 2008-2011 National Survey on Drug Use and Health.

Results: A sample majority (57%) reported smoking menthol cigarettes. Multivariate logistic regression analyses indicated that adult smokers with SMI who were younger, who had racial/ethnic minority status, who had fewer perceived interpersonal problems, and who had greater psychotic symptoms also had a significantly greater likelihood of menthol use. Smokers with SMI had a higher prevalence of menthol use relative to the general population in California overall (24%).

Conclusions: Individuals with SMI-particularly those who are younger, have racial/ethnic minority status, and have been diagnosed with a psychotic disorder-are vulnerable to menthol cigarette use. FDA regulation of menthol may prevent initiation and may encourage cessation among smokers with SMI.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Menthol smoking prevalence according to race/ethnicity among adults with serious mental illness and a California representative sample of adult smokers. California representative estimates of menthol smoking come from the 2008–2011 National Survey on Drug Use and Health,,.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Genl Psychiatry. 2004;61:1107–1115. - PubMed
    1. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. J Am Med Assoc. 2000;284:2606–2610. - PubMed
    1. Manderscheid RW, Druss B, Freeman E. Data to manage the mortality crisis. Int J Ment Health. 2008;37:49–68.
    1. Schroeder SA, Morris CD. Confronting a neglected epidemic: tobacco cessation for persons with mental illnesses and substance abuse problems. Annu Rev Public Health. 2010;31:297–314. - PubMed
    1. Tobacco Products Scientific Advisory Committee to the Food and Drug Administration. Menthol Cigarettes and Public Health: Review of the Scientific Evidence and Recommendations. Washington, DC; 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMateria... Accessed May 2012.

Publication types